JP2021503006A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503006A5
JP2021503006A5 JP2020544383A JP2020544383A JP2021503006A5 JP 2021503006 A5 JP2021503006 A5 JP 2021503006A5 JP 2020544383 A JP2020544383 A JP 2020544383A JP 2020544383 A JP2020544383 A JP 2020544383A JP 2021503006 A5 JP2021503006 A5 JP 2021503006A5
Authority
JP
Japan
Prior art keywords
binds
adbd
cancer
cells
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544383A
Other languages
English (en)
Japanese (ja)
Other versions
JP7356435B2 (ja
JP2021503006A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/060902 external-priority patent/WO2019099440A1/en
Publication of JP2021503006A publication Critical patent/JP2021503006A/ja
Publication of JP2021503006A5 publication Critical patent/JP2021503006A5/ja
Priority to JP2023117930A priority Critical patent/JP7689161B2/ja
Application granted granted Critical
Publication of JP7356435B2 publication Critical patent/JP7356435B2/ja
Priority to JP2025087327A priority patent/JP2025122150A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544383A 2017-11-14 2018-11-14 多機能性免疫細胞療法 Active JP7356435B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023117930A JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法
JP2025087327A JP2025122150A (ja) 2017-11-14 2025-05-26 多機能性免疫細胞療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762585770P 2017-11-14 2017-11-14
US62/585,770 2017-11-14
US201862717165P 2018-08-10 2018-08-10
US62/717,165 2018-08-10
PCT/US2018/060902 WO2019099440A1 (en) 2017-11-14 2018-11-14 Multifunctional immune cell therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023117930A Division JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法

Publications (3)

Publication Number Publication Date
JP2021503006A JP2021503006A (ja) 2021-02-04
JP2021503006A5 true JP2021503006A5 (https=) 2021-12-23
JP7356435B2 JP7356435B2 (ja) 2023-10-04

Family

ID=66539901

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544383A Active JP7356435B2 (ja) 2017-11-14 2018-11-14 多機能性免疫細胞療法
JP2023117930A Active JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法
JP2025087327A Pending JP2025122150A (ja) 2017-11-14 2025-05-26 多機能性免疫細胞療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023117930A Active JP7689161B2 (ja) 2017-11-14 2023-07-20 多機能性免疫細胞療法
JP2025087327A Pending JP2025122150A (ja) 2017-11-14 2025-05-26 多機能性免疫細胞療法

Country Status (13)

Country Link
US (3) US11730763B2 (https=)
EP (1) EP3710034A4 (https=)
JP (3) JP7356435B2 (https=)
KR (2) KR20250070609A (https=)
CN (1) CN111511383A (https=)
AU (2) AU2018368431B2 (https=)
BR (1) BR112020008939A2 (https=)
CA (1) CA3082410A1 (https=)
IL (2) IL274677B2 (https=)
MX (2) MX2020004935A (https=)
PH (1) PH12020550242A1 (https=)
SG (1) SG11202003168WA (https=)
WO (1) WO2019099440A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL274677B2 (en) 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
WO2021026353A2 (en) * 2019-08-06 2021-02-11 Ohio State Innovation Foundation Therapeutic extracellular vesicles
JP2023500799A (ja) * 2019-10-18 2023-01-11 トラスティーズ オブ ボストン ユニバーシティ Cal-tコンストラクトおよびその使用
MX2022011027A (es) * 2020-03-06 2022-12-13 Aleta Biotherapeutics Inc Composiciones y metodos para el tratamiento del cancer.
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
CA3175860A1 (en) * 2020-03-27 2021-09-30 The Trustees Of Indiana University Immunotherapeutic targets in multiple myeloma and methods for their identification
WO2022049217A1 (en) * 2020-09-04 2022-03-10 Miltenyi Biotec B.V. & Co. KG System for inducible expression of an adapter in immune cells
CA3212948A1 (en) * 2021-03-26 2022-09-29 David M. Hilbert Multifunctional immune cell therapies
CN117295820A (zh) * 2021-03-31 2023-12-26 盐野义制药株式会社 以ccr8作为抗原识别的嵌合抗原受体
MX2024005673A (es) 2021-11-15 2024-07-09 Arcellx Inc Polipeptidos que contienen el dominio d y usos de los mismos.
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
CN116284438B (zh) * 2022-12-28 2026-02-03 杭州凯保罗生物科技有限公司 一种Claudin2-MAGEA3融合肿瘤抗原蛋白的制备方法及其应用
WO2025168848A1 (en) 2024-02-09 2025-08-14 IMMUNEO Therapeutics GmbH Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same
LU103243B1 (en) 2024-02-09 2025-08-11 PMCR GmbH Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same
WO2025174812A1 (en) * 2024-02-12 2025-08-21 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Chimeric antigen receptor and/or synnotch receptor systems and cells and methods of their use

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7763258B2 (en) 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
EP1305437B1 (en) 2000-07-31 2010-09-01 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
JP4820055B2 (ja) 2001-12-27 2011-11-24 グライコフィ, インコーポレイテッド 哺乳動物型糖質構造を操作するための方法
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
KR101070518B1 (ko) 2002-03-19 2011-10-05 스티칭 디엔스트 랜드보위쿤디그 온데조에크 식물에서의 gntⅲ 발현
DE60333201D1 (de) 2002-09-12 2010-08-12 Greenovation Biotech Gmbh Verfahren zur herstellung von proteinen
US7781197B2 (en) 2002-12-20 2010-08-24 Greenovation Biotech Gmbh Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins
DK1587907T3 (da) 2003-01-07 2011-04-04 Dyax Corp Kunitz-domænebibliotek
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
EP1675607B1 (en) 2003-09-05 2015-10-21 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
CN1871252A (zh) * 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CN101287503A (zh) 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
GB0907251D0 (en) 2009-04-28 2009-06-10 Univ Leiden Coplymers
WO2011034947A2 (en) 2009-09-15 2011-03-24 University Of Washington Reagents and methods for modulating cone photoreceptor activity
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012167109A2 (en) 2011-06-03 2012-12-06 Massachusetts Eye & Ear Infirmary Rpgrip1 gene therapy for leber congenital amaurosis
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US20160031996A1 (en) 2013-03-14 2016-02-04 Csl Limited Anti il-3r alpha agents and uses thereof
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
GB201306634D0 (en) 2013-04-11 2013-05-29 Univ Bristol Cage-like particles
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
IL248102B (en) 2014-05-02 2022-07-01 Genzyme Corp aav vectors for gene therapy of the central nervous system and retina
AU2015289644A1 (en) 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
WO2016154621A1 (en) * 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
KR20160126340A (ko) 2015-04-23 2016-11-02 삼성전자주식회사 3중-나선 다발 단백질 및 이의 용도
WO2017032867A1 (en) * 2015-08-27 2017-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a lung cancer
CA3005042A1 (en) 2015-11-13 2017-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-bcma polypeptides and proteins
AU2017355218B2 (en) * 2016-11-02 2024-02-22 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
CN107254447B (zh) * 2017-06-01 2020-10-16 刘未斌 Anti AFP CAR-T细胞及其制备方法和应用
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL274677B2 (en) 2017-11-14 2025-01-01 Arcellx Inc Therapies with multifunctional immune system cells
CA3212948A1 (en) 2021-03-26 2022-09-29 David M. Hilbert Multifunctional immune cell therapies

Similar Documents

Publication Publication Date Title
JP2021503006A5 (https=)
JP6867347B2 (ja) 免疫療法のためのエンゲージャー細胞
ES2951552T3 (es) Polipéptidos inmunomoduladores y composiciones y métodos relacionados
JP7082574B2 (ja) 免疫療法用改変細胞
KR102763121B1 (ko) 치료적 면역 세포의 효능의 향상 방법
CN108715859B (zh) 靶向cd22的嵌合抗原受体及其应用
CA3177829A1 (en) Chimeric antigen and t cell receptors and methods of use
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
AU2019243453A1 (en) Methods of making and using guidance and navigation control proteins
WO2019032916A1 (en) CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTES WITH LYMPHOCYTE T-RECEPTOR DEFICIENTS AND METHODS OF USE THEREOF
WO2019005641A1 (en) GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
JP2018504094A (ja) Fc受容体様5を標的とするキメラ抗原受容体およびその使用
JP2018529327A5 (https=)
AU2026201842A1 (en) Engineered cells, T cell immune modulating antibodies and methods for using the same
JP2015527070A5 (https=)
CN107847587A (zh) Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
CN113195535A (zh) 用于连接表达car的免疫细胞与抗原呈递细胞的双特异性多肽及其用途
JP2023520410A (ja) Cd33を標的にするキメラ抗原受容体
JP2021514188A (ja) Foxp3標的因子組成物と養子細胞療法のための使用方法
JP2023535371A (ja) 免疫抑制シグナル伝達をリダイレクトするためのキメラMyD88受容体ならびに関連する組成物および方法
US20250222030A1 (en) NK cells for Cell Therapy
CN117999344A (zh) Nkg2d嵌合抗原受体和pd1抑制剂联合治疗癌症的方法和药物
NZ805406A (en) Multifunctional immune cell therapies